Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

PURPOSE: Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study. METHODS: Patients with advanced solid m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Chemother Pharmacol
Main Authors: Abou-Alfa, Ghassan K., Lewis, Lionel D., LoRusso, Patricia, Maitland, Michael, Chandra, Priya, Cheeti, Sravanthi, Colburn, Dawn, Williams, Sarah, Simmons, Brian, Graham, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado: 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5520972/
https://ncbi.nlm.nih.gov/pubmed/28523596
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3315-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares